Status
Conditions
Treatments
About
The "LYNC" clinical investigation aims to confirm the clinical benefits, performance and safety of the Lync® device when implanted in the toes for the treatment of arthritis and correction of bone misalignments.
The main objective of the study is to confirm the clinical benefits of the Lync® device for the treatment of arthritis and the correction of bone alignment default, by evaluating the restoration of the functional capacities of the forefoot at 3 -4 months post-operative follow-up with AOFAS-LMIS score.
Full description
The clinical evaluation demonstrates that the clinical benefits, performance and safety of the Lync® device when implanted in the toes for the treatment of arthritis are not covered by any clinical data on similar devices.
The "LYNC" clinical investigation aims to confirm the clinical benefits, performance and safety of the Lync® device on 76 cases (feet) when implanted in the toes for the treatment of arthritis and correction of bone misalignments.
The main objective of the study is to confirm the clinical benefits of the Lync® device for the treatment of arthritis and the correction of bone alignment default, by evaluating the restoration of the functional capacities of the forefoot at 3 -4 months post-operative follow-up with AOFAS-LMIS score as primary endpoint.
The secondary objectives of the study are:
The secondary endpoints associated with the secondary objective are:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient requiring treatment of arthritis and/or correction of bone alignement defaultin the toes (mallet toes, claw toes, hammer toes),
Use of the Lync® intramedullary osteosynthesis implantable medical device,
No associated surgical procedures except:▪Flexor release/tenotomy
Adult patient,
Patient capable of respecting the prescriptions and recommendations of his surgeon,
Patient able to read and understand the information note and the consent form,
Patient able to sign a consent form.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
76 participants in 1 patient group
Loading...
Central trial contact
Flora PEYRET; Manon GUIGUEN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal